Eli Lilly and Company– tag –
-
Leading AI Drug Discovery Platforms Evolve from Candidate Generation to Protein Design in 2026, Driven by Eli Lilly-Insilico Medicine $2.75 Billion Partnership
The AI Journal USA Overview In 2026, AI drug discovery platforms, led by Converge Bio, Xaira Therapeutics, and Generate Biomedicines, have advanced beyond mere drug prediction to encompass candidate generation, antibody engineering, targ... -
Precision Science Fuels Biopharma M&A Surge: Q1 2026 Hits $65B+, Marking Industry’s ‘Full Recovery’
BioSpace / PwC, Pharmaceutical Technology / PwC USA Overview PwC's latest report declares the biopharma ecosystem 'fully recovered,' with Q1 2026 M&A deal values exceeding $65 billion, marking the largest quarter since 2020. This rob... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s... -
Oral GLP-1 Receptor Agonist Elecoglipron Achieves Up to 11.8% Weight Loss and 7% Blood Sugar Reduction in Phase 2b Trials
Medical News Today (citing The Lancet) International Overview Once-daily oral GLP-1 receptor agonist elecoglipron demonstrated significant efficacy in its Phase 2b SOLSTICE clinical trial. Obese and overweight adults achieved up to an 11... -
Top Cell Therapy Startups Secure Significant Funding for Commercialization, Infrastructure, and Novel Modalities
New Market Pitch USA Overview Leading cell therapy startups are attracting substantial investment, indicating investor confidence in high-risk technical innovation. Companies like Orca (near-commercial assets), Cellares (manufacturing in... -
GLP-1 Market Heats Up with Oral Therapies and Triple Agonists for Obesity, Metabolic Health Opportunity Nears $150 Billion
DataM Intelligence USA Overview The GLP-1 market is experiencing intense competition, driven by the development of oral therapies and triple agonists for obesity and metabolic health, with the market opportunity projected to reach $150 b... -
Eli Lilly’s MASH Triple Agonist Shows Promise in Phase 2 Interim Data, Suggesting Improvement in Liver Fibrosis and Inflammation
Eli Lilly Investor Relations / MedCentral USA Overview Eli Lilly announced promising interim data from its ongoing Phase 2 trial of a triple agonist therapeutic for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data sugges... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ... -
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea...
